For 25 years, I’ve built a career around storytelling—elevating Korean-American voices through over 1,400 interviews and nearly 300 issues of print and digital media. What I’ve learned is this: stories don’t just preserve identity—they shape opportunity.
Now, we enter a new chapter.
Korea has already transformed the world’s cultural landscape—from K-pop and K-drama to food and fashion. But the next wave of influence will come from a deeper source: our innovation.
Korean biotech, backed by two decades of R&D and billions in investment, is producing globally competitive technologies in diagnostics, therapeutics, digital health, and AI. Yet, the U.S. market remains difficult to penetrate—not for lack of quality, but because of local barriers: FDA strategy, clinical readiness, regulatory alignment.
At the same time, U.S. hospitals, CROs, and venture firms are actively searching for early-phase innovation—but they demand clear validation, data, and readiness.
K-BioSync 2025 was created to bridge that gap.
This is not an expo. It is a pilot platform—a curated entry point for 6–10 select Korean companies to meet with real decision-makers in the U.S. life sciences ecosystem. Through evaluator committees composed of hospital leaders, CROs, and fund managers, we aim to facilitate not just meetings, but matches.
Our mission is clear: support meaningful, strategic partnerships between Korean innovation and U.S. infrastructure.
Why New Jersey?
While Boston and the Bay Area dominate headlines, New Jersey offers unmatched strategic value: Home to 14 of the world’s top 20 pharmaceutical companies
Dense networks of hospitals, universities, and innovation hubs
Direct access to New York City’s regulatory and financial capital
Pro-business, R&D-friendly policies at the state and county levels
It is not just a biotech hub. It is a bridge—between continents, sectors, and opportunity.
Why Now?
Because timing matters.
Korea’s biotech industry is ready. Our companies are IP-rich, globally trained, and eager to expand. The U.S. is open—but selective. And we are prepared to meet that bar. This pilot, co-hosted with Choose New Jersey and BioNJ, represents a public-private alliance with both credibility and commitment. Their teams have offered more than partnership—they are active co-builders of this initiative, from structure to curation.
Who We Are
K-BioSync is produced by KORISE, a new media and strategy platform built on the 25-year legacy of The M Magazine. It stands for “Korea + Rise”—and reflects our belief in Korea’s global ascent across business, culture, and science.
As Chair of the HCCC Korean Chapter, I’ve worked closely with both Korean and U.S. institutions to ensure this platform is not only authentic—but strategic. This is just the beginning. Our vision is to grow K-BioSync into a scalable, multi-sector gateway connecting Korean innovation with global capital, media, and clinical partners.
But it starts here—with this pilot, and with you. If you are reading this, you are part of this ecosystem. Whether you’re a Korean company seeking real partners, or a U.S. institution exploring global innovation—this platform was designed for you.
Let’s make it meaningful. Let’s make it matter.
Sylvia Kim Founder & Publisher, KORISE Chair, HCCC Korean Chapter
K-BioSync 2025
Table of Contents
Executive Overview
Vision, Purpose & Strategic Goals of K-BioSync 2025
Who’s Behind This Organizers, Advisors & Core Leadership – Sylvia Kim, KCED, HCCC Korean Chapter
Why Now
Global Momentum of K-Bio & Urgency of U.S. Market Entry
Why New Jersey
Comparative Advantages vs. Boston, SF & Texas
Program Summary
Structure, Matching System, Expert Clinics
How We Curate (Korea)
Company Evaluation Criteria, Selection Process, Committee
How We Curate (U.S.)
Institutional Matching Logic, Clinical & Commercial Fit
3-Day Event Schedule
October 15–17, 2025 | Full Timeline
BIO International 2025 Special Feature On-the-Ground Insights & Reflections from Boston
Messages from Dignitaries, Industry Leaders & Influencers
How to Join
Participation Guide for Korean Companies & U.S. Institutions
Contact & Inquiries
Get in Touch | Project Lead & Advisory Contact Info
Phil Murphy, Governor of New Jersey
On behalf of the State of New Jersey, I want to extend my warm congratulations to Sylvia Kim and the entire K-BioSync 2025 team on the launch of this exciting initiative.
Since taking office in 2018—and being re-elected in 2021—my administration has focused on creating meaningful economic opportunities across our state, with a special emphasis on innovation and global collaboration
New Jersey is proud to stand as a global leader in life sciences: home to 14 of the world’s top 20 pharmaceutical companies, a robust research ecosystem, and a growing Korean-American bio community. K-BioSync is the kind of strategic, mission-driven partnership that aligns perfectly with our goals to connect talent, technology, and opportunity across borders.
Your program is not simply an event—it is a strategic platform that supports real, transaction-ready collaboration between Korean biotech innovators and U.S. institutions. I am confident that K-BioSync will serve as a powerful gateway for deeper, sustainable engagement—and serve as a model for future public-private collaboration.
Phil Murphy
Governor, State of New Jersey 56th Governor since January 2018
Dr. Robert Garrett, CEO, Hackensack Meridian Health
As CEO of Hackensack Meridian Health, I am pleased to congratulate the launch of K-BioSync 2025—an initiative that speaks directly to the future of global clinical collaboration.
At Hackensack Meridian, we believe in advancing care through innovation. With our extensive research network, data capabilities, and patient-first mission, we see real potential in this effort to foster stronger clinical, academic, and commercial partnerships between the U.S. and Korea.
The structure of K-BioSync—as a curated, high-impact matching program— demonstrates a nuanced understanding of what early-stage biotech companies truly need to succeed: regulatory insight, access to trials, and the right ecosystem of mentors and partners.
We look forward to engaging with the cohort and exploring future collaborations that improve lives, accelerate therapies, and enhance cross-border medical innovation.
Congratulations on this meaningful milestone.
Dr. Robert Garrett Chief Executive Officer Hackensack Meridian Health
Dr. Michelle Kim, General Partner, Vie Ventures (Boston)
Congratulations to the organizers of K-BioSync 2025 for launching such a thoughtfully designed platform for cross-border biotech collaboration.
As an investor focused on immunology, oncology, and advanced therapeutics, I understand the complexities that early-stage companies face when entering a market like the United States. This program addresses critical gaps—especially in FDA readiness, clinical partnerships, and go-to-market strategy—that often prevent excellent Korean firms from scaling globally.
What makes K-BioSync promising is not just its ambition, but its structure: focused, selective, and execution-driven. We need more of this type of ecosystem thinking—where innovation is not just discovered, but guided into real-world outcomes.
I look forward to meeting this year’s selected companies and engaging with the broader U.S.–Korea biotech community this initiative is helping to build.
With admiration and support,
Michelle Kim, PhD General Partner Vie Ventures
Dr. Joon-Ho Park, President, KoreaBio
On behalf of KoreaBio, I extend my heartfelt congratulations on the launch of K-BioSync 2025.
Korea’s biotechnology sector is entering a new era of global expansion. As we continue to invest in R&D, talent, and digital transformation, it is vital that we also build trusted, high-quality pathways into key global markets—especially the United States.
K-BioSync offers a concrete and credible framework for this next stage of growth. Its focus on selective company support, expert evaluation, and institutional matchmaking ensures that Korean firms will not only showcase innovation, but form lasting partnerships grounded in regulatory and clinical rigor.
We at KoreaBio are excited to support this pilot effort and look forward to seeing it grow into a long-term bridge between our ecosystems. This is a commendable first step—and a promising new platform for Korean biotech leadership.
Dr. Joon-Ho Park
President Korea Biotechnology Industry Organization
(KoreaBio)
Why Now: Why K-BioSync 2025 Must Happen This Year
The Global Moment Korea’s Biotech Has Been Building Toward, After two decades of infrastructure-building, talent cultivation, and deep R&D investment, Korea’s biotech industry has arrived at a commercial inflection point—and the time to act is now.
This is not just another industry forum.
K-BioSync 2025 is a strategic answer to a historic alignment of policy shifts, regulatory windows, investment trends, and talent maturity—on both sides of the Pacific.
Korea Has Entered Its Biotech Prime
• Record-breaking export growth: Korean biopharma exports reached $1.67 billion in Q1 2025 alone, a 30% YoY increase—the highest in history.
• Massive licensing activity: Over 10 trillion ($7.5B) in global licensing deals in the past year, signaling commercial readiness.
• Top-tier infrastructure: From Songdo to Osong, Korea is home to world-class bio-clusters and GMP-ready facilities.
• Mature human capital: A new generation of FDA-literate, U.S.-trained Korean scientists and founders is ready for global partnership—not just visibility.
“The R&D era is over. Korea’s biotech is now export-ready.”
The U.S. Regulatory Window Is Open—But Won’t Stay Open
• FDA’s Diversity Action Plans (effective 2025) mandate global enrollment strategies in clinical trials.
• Global hospitals and CROs are actively seeking Asia-based partners to meet compliance thresholds.
• Korean firms, with strong early-stage IP, are well-positioned—but need matching structures to bridge the U.S. trust gap.
“This is not a branding exercise. This is FDA timing.”
The U.S. Investment Landscape Is Shifting East
• Post-China diversification: U.S. VCs are increasingly looking toward Korea as a cost-effective, innovation-rich alternative.
• Biotech-specific VCs (e.g., Third Rock, Vivo Capital, Vie Ventures) are seeking clinically validated, FDA-pathway-ready startups from Asia.
• But they demand:
Clear regulatory strategy
Data room readiness
Real U.S. market entry plans
“Without a curated platform like K-BioSync, those deals won’t happen.”
Korea’s Scientific Generation Is Finally Global-Ready
This generation is:
• Fluent in regulatory language
• Trained in multinational environments
• Ready to commercialize They don’t need awareness. They need transactional structures: co-development, co-trials, licensing, scaling.
“They’re not here to be introduced. They’re here to do business.”
Government Timing: Policy Realignment Creates a Window
• Korea’s new administration (2025) is resetting industrial policy, global trade strategy, and export incentives.
• Public-private programs are being updated rapidly to support international transactions—not just promotion.
• U.S. pressures (tariffs, supply chain diversification) have pushed K-Bio to the top of Korea’s export agenda.
“Regulators are moving. Investors are moving. This opportunity won’t last 12 more months.”
K-BioSync 2025 is Not Just Timely. It’s Necessary.
• A curated platform for matchmaking, not just showcasing
• Real pathways for FDA validation, clinical collaboration, and U.S. market entry
• A rare alignment of government support (CHOOSE NJ, BioNJ) + institutional partnership + business objectives “This is the moment Korea’s biotech has prepared for. And this is the platform that will unlock it.”
Why New Jersey Not Just a Location A Strategic Launchpad for Global Bio Collaboration
When it comes to biotech innovation in the U.S., Boston and Texas are often top-of-mind. Yet New Jersey has quietly become one of the most strategically positioned, resource-rich, and globally connected bio and healthcare hubs in the country—and is uniquely suited to serve as a launchpad for Korean biotech companies.
Location with Leverage
New Jersey sits at the center of the Northeast bioscience corridor, within close proximity to:
New York City’s capital markets and global media
Philadelphia’s university and research ecosystem
The FDA, NIH, and CMS in the greater D.C. region
This strategic geography means that companies launching in NJ can access decision-makers, funders, regulators, and global partners within hours.
Legacy of Life Sciences Leadership
New Jersey is not new to biotech—it’s known as the “Medicine Chest of the World”, home to:
Over 3,300 life sciences establishments
14 of the world’s top 20 pharmaceutical companies with a U.S. footprint here (e.g. J&J, Merck, BMS, Novartis)
Robust CROs, CMOs, and hospital networks including Hackensack Meridian, RWJBarnabas Health, and Atlantic Health System
Unlike saturated hubs like Boston, NJ offers room to grow—with available lab space, incentives, and deep
institutional support for international entrants.
Institutional Partnership Capacity
NewJerseyishometoproactive,state-levelinstitutions focused on global business development, including:
Choose New Jersey – the state’s premier economic development agency
BioNJ – one of the most engaged life sciences associations in the U.S.
NJEDA, HINJ, and strong ties to Korean-facing trade organizations
These organizations don’t just support companies— they partner with them to develop infrastructure, matchmaking opportunities, and long-term growth.
Accessible & Scalable Market Entry
Unlike Boston or San Francisco—where entry costs andinstitutionalbarriersarehigh—NewJerseyoffersa realistic and scalable entry point for global companies. Korean firms can:
This makes NJ a lower-risk, higher-engagement ecosystem, particularly ideal for firsttime global expansion.
Global Mindset, Korean-Ready
New Jersey is home to the 3rd largest Korean population in the U.S., a growing Korean-American professional class, and established cultural and economic bridges with Korea through its Chambers, universities, and consulates.
WithorganizationslikeHCCCKoreanChapter,KOTRANewYork,andKHIDIpartners on the ground, the Korea-NJ link is not theoretical—it’s already active.
Sustainability Beyond the Event
K-BioSync is not a one-time event. Through New Jersey’s public-private partnerships and strong Korean-American community leadership, it can become an annual platform with:
Ongoing evaluation and mentoring programs
Permanent institutional and clinical partners
Media and policy visibility for both Korean and U.S. stakeholders
WhereBostonmaybetooeliteandTexastoofragmented,NewJerseyisbalanced,agile, and ready.
K-BioSync 2025: Bridging Korean Innovation with U.S. Bio Leadership
Executive Overview
K‑BioSync 2025 is a high impact pilot program and curated industry platform that aims to strategically connect South Korea’s most promising biotech, medtech, and health innovation companies with U.S. based hospitals, investors, and clinical institutions.
Scheduled for October 15–17, 2025 in New Jersey, this 3 day initiative is co hosted by Choose New Jersey and BioNJ, two of the region’s most influential economic and bioscience organi zations. More than a simple expo, K‑BioSync is designed as a transaction ready engagement platform—where real companies meet real partners for high level validation, joint develop ment, and long term U.S. entry.
Vision
To become the definitive U.S. gateway for global Korean biotech, supporting sustainable cross border partnerships through structured, trusted, and well curated collaboration models.
Purpose
Facilitate 1:1 strategic connections between Korean innovators and U.S. institutions based on mutual interest and clinical/commercial fit.
Bridge regulatory and operational gaps (FDA pathway, clinical readiness, IP structuring) through targeted mentorship and pre matching.
Showcase Korea’s bio industry strength to U.S. audiences with strong institutional backing and press exposure.
Why Now?
While Korean life science companies have demonstrated tremendous innovation in diagnos tics, gene/cell therapy, and medical devices, many struggle to scale beyond domestic markets due to limited U.S. regulatory familiarity and insufficient local networks. Meanwhile, U.S. insti tutions are increasingly open to global collaboration—but lack structured pathways to assess and partner with credible overseas ventures.
K‑BioSync 2025 meets this critical need by establishing a pilot ecosystem that combines:
Rigorous selection and evaluation process for participating Korean firms
Customized U.S. partner matchmaking based on institutional needs
Trusted public private coordination with high level endorsement
Bilingual media outreach to maximize global visibility
2025 Pilot, 2026 Expansion
K‑BioSync 2025 will serve as a proof of concept for a larger, recurring initiative aimed at launch ing a fully scaled Korea U.S. bio collaboration platform in 2026. Participating stakeholders in this year’s pilot will help shape the future of transnational biotech matchmaking—grounded in shared value, mutual trust, and measurable outcomes.
Who is Behind This: Vision Led by Cultural Strategy, Backed by Institutional Partnership
K-BioSync 2025 is led by Sylvia Kim
A Korean American publisher, media strategist, and cross cultural community advocate with over 25 years of experience bridging Korea and the U.S. through media, entrepreneurship, andinstitutionaldialogue.AsthefounderofKCED(KORICulture&EconomicDevelopment LLC),SylviahaslongchampionedinnovativeplatformsthatelevateKoreanidentityandcon nect it with global markets.
A respected voice in the Korean American ecosystem, Sylvia is also the publisher of The M Magazine, a legacy bilingual publication celebrating Korean leadership and cultural excel lence for nearly three decades.
This initiative is exclusively developed in partnership with the Hudson County Chamber of Commerce (HCCC) Korean Chapter, where Sylvia serves as Chair. The event is further sup ported by the HCCC Korean Chapter Advisory Council, a group of industry professionals andcivicleadersdedicatedtofosteringimpactfulKorean American economic engagement.
Strategic Partners & Ecosystem Support
K‑BioSync 2025 is made possible through collaborative efforts with: Choose New Jersey, the state’s leading economic development engine BioNJ, New Jersey’s voice for the life sciences sector
A growing coalition of stakeholders including NJEDA, Korean trade and health agencies (e.g. KOTRA, KHIDI), and Korean bio industry leaders
This program is further strengthened by an active network of U.S. based professionals including:
Local hospitals, accelerators, and innovation funds that recognize the value of curated Kore an biotech partnerships
Connected to Korea
K‑BioSync 2025 is not a one off event—it is part of an ongoing effort to build a trusted, curated pipeline between Korea’s bio sector and the U.S. market. Sylvia and her team are actively working with:
Official Korean organizations including KoreaBIO, KOTRA, KHIDI, and key regional associations
A shortlist of Korean biotech companies pre selected based on potential U.S. entry readiness
Media platforms in Korea and the U.S. to maximize visibility and credibility
K‑BioSync 2025:ACurated Gateway for Cross‑Border Bio Collaboration
From Connection to Conversion:ANew Model for U.S.–Korea Biotech Partnership
In a global landscape where biotech innovation must move faster, cross borders more effectively, and engage stakeholders with precision, K-BioSync 2025 emerges as a new kind of platform—one that moves beyond the traditional expo. Built as a high-efficiency, curated collaboration program, K-BioSync is designed to foster structured, outcome-oriented partnerships between Korea’s most promising biotech firms and leading institutions in the U.S. life sciences ecosystem.
Over the course of three tightly programmed days, K-BioSync offers a hybrid format of pre-qualified matchmaking, thematic expert clinics, and bilateral roundtable exchanges. Instead of open-floor booths and broad traffic, the program delivers closed-door strategic engagements: investor briefings, clinical partner introductions, policy panels, and small-format technology showcases. Each interaction is prealigned based on institutional needs—from oncology and diagnostics to AI therapeutics and cell/gene therapy pipelines—ensuring that every meeting is purposeful and pre-qualified.
The core strength of K-BioSync lies in its fit-driven matchmaking protocol. Korean companies are carefully screenedbyabinationalevaluatorcommitteecomposedofU.S.VCs,regulatoryattorneys,innovationleads from hospitals, and economic development leaders. This process ensures that selected participants meet a set of criteria around science maturity, FDA readiness, and commercialization potential. On the other side, U.S. institutions are invited to share their clinical priorities, unmet needs, and strategic innovation areas. What follows is not random networking—but strategic pairing, accompanied by shared company dossiers, curated introductions, and post-event facilitation that can include MOU support or deal-structuring consultations.
To support these connections, K-BioSync features a series of Expert Clinics, where Korean firms receive direct mentorship from U.S. advisors. Topics span FDA regulatory guidance, reimbursement strategy, licensing/IP readiness, clinical trial preparation, and investor pitch coaching. Sessions are tailored by domain and offer bilingual, cross-border insights grounded in real operational experience. Whether preparing for IND filing or seeking U.S. co-development partners, participants leave with actionable pathways—not just business cards.
Importantly,thestructureofK-BioSyncisdesignedtocreatevalueforallsides.Koreanbiotechstartupsgain trusted access to high-value U.S. stakeholders, as well as market localization support and media amplification. U.S. hospitals and CROs discover globally competitive technologies primed for clinical collaboration. VCsgainearlyvisibilityintoAsia-originatedinnovationswithSeriesAorBpotential.Andpolicystakeholders from both countries are given a scalable pilot for fostering long-term public–private cooperation in biotech diplomacy.
In a world where large expos often fail to deliver follow-through, K-BioSync positions itself as the alternative—a strategic platform built on trust, alignment, and outcomes. It is not just an event, but a model. And it begins here—with Korea’s most forward-facing innovators and America’s most open-minded partners— meeting not on the floor, but at the table.
K-BioSync 2025 ñ Full Program Schedule
October 15ñ17, 2025 | New Jersey
DAY1–October15(Wednesday)
Theme: Market Entry & Vision Building
09:00AM–Registration&WelcomeCoffee
Participants check in, receive badges, and enjoy light re freshments in a casual networking space. A soft opening to initiate connections.
10:00AM–OpeningCeremony
Formal kickoff of K BioSync by Studio KORISE, Choose New Jersey, and BioNJ. Includes opening remarks out lining goals, partners, and expectations.
10:30AM–KeynoteAddress
A prominent U.S. biotech leader delivers a keynote on the strategic importance of Korea’s biotech industry in a globalized innovation economy.
11:15AM–U.S.BiotechMarketBriefing
In depth presentation from Choose NJ and BioNJ about New Jersey’s biotech ecosystem, business incentives, R&D assets, and entry pathways.
12:00 PM – Group Photo & Networking Lunch
Commemorative group photo with all participants, followed by lunch buffet. Opportunities for cross border mingling and informal discussions.
01:00PM–KoreanCompanyIntroductionI
Curated selection of 6–8 Korean companies present their biotech innovations in brief pitch format, targeting investors, hospitals, and U.S. partners.
02:00 PM – Panel Discussion
Panel of legal, IP, and FDA experts discuss how Korean companies can prepare for U.S. entry, covering regulato ry timelines and IP protection tips.
03:00 PM – Partner Showcase
Attendees explore booths hosted by legal firms, VC firms, real estate consultants, hospitals, and incubators. Designed for targeted introductions.
04:00PM–ExpertClinics
Small group workshops led by U.S. experts: Track A cov ers FDA/IP strategy, Track B focuses on investment pitch feedback and deal structuring.
05:30PM–EveningWelcomeReception
Evening reception to welcome delegates, featuring wine and finger foods. Hosted by local partners to build relaxed, meaningful connections.
DAY2–October16(Thursday)
Theme: Precision Matching & Deal Building
09:00 AM – Coffee Connects
Startup to startupandinvestor to founder informal networking
02:00–05:00PM–PrecisionPartneringSessions 1:1pre-matchedmeetingswithinvestors,hospitals,VCs, and firms
05:00 PM – Investor Roundtable
U.S. venture investors share deal makinginsightsand readiness criteria
06:00PM–PrivateExecutiveDinner(InviteOnly)
High level closed doorconversationamongleadership & decision makers
DAY3–October17(Friday)
Theme: Visibility, Storytelling & Scale-Up
09:00AM–BreakfastBriefing
Overview of U.S. public grant programs such as SBIR/ STTR, NSF, and state level funding for early stage bio tech companies.
10:00AM–GlobalMediaDay
Dedicated press time for Korean and U.S. media to engage with Korean startups, including Q&A, live inter views, and press photo ops.
11:00AM–InnovationWorkshops
Parallel innovation sessions led by U.S. and Korean ex perts: themes include licensing, AI health convergence, and digital therapeutics.
2:30PM–AppreciationLunch
Final lunch to celebrate the program’s success, offer thank yous, and introduce next steps including follow up meetings and 2026 plans.
02:00PM–SiteVisit(Optional)
Delegates who sign up will visit a NJ biotech innovation zone, such as a major lab facility, university incubator, or health tech campus.
04:00PM–FinalGroupPhoto&Departure
Closing group photo and farewell comments. Coordi nated departure logistics and recap of key results and takeaways from the 3 day event.
Choose New Jersey
Empowering Global Growth Through Strategic Partnership
Choose New Jersey is New Jersey’s premier economic development organization, dedi cated to attracting investment and growing the state’s economy by supporting both do mestic and international businesses. Founded as a privately funded nonprofit, Choose NJ operates with the agility of a business and the influence of a government-backed agen cy—making it a uniquely effective partner for global innovation driven industries.
At the heart of Choose New Jersey’s mission is the goal of making New Jersey a globally connected hub for life sciences, technology, advanced manufacturing, and sustainability. The organization works closely with international governments, trade associations, aca demic institutions, and corporate leaders to help companies expand into the U.S. market with confidence.
For the life sciences sector, Choose New Jersey offers:
Access to New Jersey’s world class pharmaceutical and biotech corridor
Market entry consulting and site selection services
Regulatory guidance and incentives navigation
Institutional connections to hospitals, incubators, and research parks
Long-term collaboration opportunities with global firms and startups alike
Why Korean Companies Should Pay Attention:
Choose New Jersey maintains a dedicated office in Seoul, offering bilingual support and local expertise to Korean life sciences companies. Korean firms can benefit from soft land ing programs designed to support every phase of U.S. entry—from incorporation and legal setup to connections with hospitals, venture firms, and real estate advisors. Moreover, Choose NJ has successfully supported Korean companies across sectors and provides direct links to clinical trial opportunities, joint R&D, and public private partner ships with leading institutions such as Rutgers University and Hackensack Meridian Health.
As a co host of K BioSync 2025, Choose NJ brings not only regional insight and credi bility but also a vision for sustainable innovation exchange between Korea and the Unit ed States. Their involvement ensures that Korean biotech companies are not just intro duced—but integrated—into New Jersey’s life sciences ecosystem.
www.choosenj.com
BioNJ
Because Patients Can’t Wait® Building the Future of Life Sciences
BioNJ is the leading life sciences trade association in New Jersey, representing more than 400 member companies across biopharma, medical devices, digital health, and clinical research. Established in 1994, BioNJ has grown into a nationally recognized voice for in novation in healthcare—serving as both an advocate for industry and a connector across the public private ecosystem.
What sets BioNJ apart is its unwavering focus on translating scientific innovation into pa tient impact. Its mission—Because Patients Can’t Wait®—underscores every program, event, and initiative it delivers. From startup support and regulatory workshops to CEO forums and venture roundtables, BioNJ has become a trusted platform for growth stage and mature biotech enterprises alike.
Core services and strengths include: Policy advocacy at the state and federal level Strategic events including BioPartnering Conferences and C Suite Summits Workforce development and talent retention programs Industry data, market trends, and investor matchmaking Global collaboration initiatives with international clusters and embassies
Why This Matters for Korean Biotech:
BioNJ offers Korean companies direct access to FDA and U.S. regulatory experts, en abling early stage guidance to minimize risks in entering the U.S. market. Participation in BioNJ events and membership confers credibility and visibility within the American bio pharma industry.
Moreover, BioNJ is a gateway to potential licensing, joint ventures, and strategic partner ships with U.S.-based pharmaceutical firms, CROs, and research hospitals. Korean com panies will also benefit from insights into U.S. reimbursement systems, clinical trial design, and state/federal grant opportunities such as SBIR/STTR and NIH collaborations.
As a co host of K BioSync 2025, BioNJ provides Korean innovators with the tools, net works, and institutional trust to move from opportunity to real traction in the U.S. biotech space.
www.bionj.org
How We Curate: Korean Company Selection & Evaluator Committee
Connecting Innovation with Opportunity – Selectively. Strategically.
Globally.
K-BioSync 2025 is not another trade show. It is a curated gateway to the U.S. biotech ecosystem—where only the most promising Korean innovators are introduced to decision-makers across hospitals, VC firms, CROs, and public agencies. At the heart of this effort is a rigorous, multi-layered curation process grounded in relevance, regulatory realism, and relationship-building.
We begin with a strategic screening by the Studio KORISE editorial and outreach team, identifying startups with clear market potential, compelling science, and a genuine commitment to long-term U.S. expansion. From there, our Evaluator Committee— composed of leaders from BioNJ, Choose New Jersey, major hospital systems, and FDA/IP specialists—reviews each company through the lens of the American market.
This process isn’t about gatekeeping—it’s about readiness and fit. Companies are evaluated across scientific merit, market alignment, clinical partnership potential, regulatory strategy, and licensing opportunities. Even applicants who are not selected receive feedback to help refine their positioning for future success.
Unlike global expos that reward presence through payment, K-BioSync is merit-based. All meetings are pre-curated—not just matched, but deeply aligned—with institutional interests, ensuring meaningful outcomes. For Korean companies, this offers not only credibility in the U.S. but access to relationships, visibility through BioNJ and Choose NJ, and inclusion in Korean and U.S. biotech media.
Importantly, this pilot is also a gateway: companies selected for 2025 will be considered first for K-Bio Gateway 2026, an expanded platform of roadshows, site visits, and global deal facilitation.
Our evaluators range from life sciences VCs and FDA attorneys to innovation leads at major hospitals and ecosystem builders at BioNJ. Together, they help us ensure that what’s introduced here is not just exciting—but executable.
K-BioSync exists to close the credibility and connectivity gap—not with volume, but with precision. This isn’t about showing up. It’s about showing promise—and making that promise visible to the right people.
How We Curate (U.S. Side) Strategic Matching with U.S. Institutions,
Based on Need, Capacity, and Intent
For Korean biotech firms ready to cross borders, breaking into the U.S. market is no longer about visibility— it’s about precision. K-BioSync is engineered to eliminate guesswork by aligning Korean innovation with U.S. institutional readiness. From hospitals and CROs to VC firms and regulatory advisors, the matchmaking is rooted in intent, not optics.
A Korean Question, An American Answer
Korean companies entering the U.S. often ask:
“Who are the right hospitals or partners for us?”
“How far along do we need to be with the FDA?”
“How do we get to decision-makers, not gatekeepers?”
“Can someone help us communicate our story properly?”
“Will this lead to real opportunities?”
These questions are valid. And K-BioSync was built to answer them—strategically and tangibly.
Matching with Meaning
K-BioSync’s matching framework is developed with input from U.S.-based stakeholders who understand both the clinical landscape and business dynamics. The core principles:
Relevance over scale: Every meeting is based on sectoral alignment (oncology, rare diseases, AI diagnostics, etc.), development stage, and institutional interest.
FDA-pathway awareness: Even if not FDA-approved, companies that show regulatory awareness and realistic timelines are given a platform.
Localized communication: Through Studio KORISE, we support companies in shaping their story to resonate with American investors and clinicians.
Post-match follow-up: Matching doesn’t end on-site. With support from BioNJ and Choose NJ, we help ensure continuity after introductions—via digital meetings, site visits, or advisory calls.
What Participating Korean Companies Receive Institutional Mapping
Matched profiles of U.S. hospitals, VC firms, accelerators, and CROs based on mutual interest.
Advance Dossier Optimization
Translation, editorial review, and strategic packaging of pitch decks, clinical data, and company summaries. Cross-Cultural Coaching
Support for executive teams on how to pitch, explain regulatory readiness, and position their pipeline for a U.S. audience.
Onsite & Follow-Up Support
Interpretation if needed, and structured guidance post-event with feedback and next steps.
Preparing for the Match
Korean companies are advised to prepare:
l A visual, data-backed IR deck with clear FDA roadmap, pipeline status, and collaboration ask
l A one-page summary following K-BioSync format
l Defined ideal partner types (hospital, investor, CRO, etc.)
l Realistic post-event follow-up capacity to sustain conversations
Why U.S. Institutions Are Engaged
U.S. partners welcome K-BioSync because:
l It filters noise and delivers relevance
l It allows them to explore Korean innovation without the costs of global scouting
l It is backed by trusted regional entities like BioNJ and Choose New Jersey
l It offers pre-curated partnerships instead of cold outreach
“K-BioSync isn’t about the number of booths. It’s about delivering the right conversation at the right time—with the right person.”
K-BioSync is your quiet but powerful gateway—not just to be seen in the U.S., but to be taken seriously.
Curating the Future of Korea–U.S. Biotech Collaboration
How one pilot initiative is changing how global biotech partners are chosen, matched, and activated.
I. INTRODUCTION: The Moment We’re In
In June 2025, San Diego’s BIO International Convention echoed with languages from around the world, with one language getting louder: Korean. Korea has rapidly emerged as a critical player in global biotech, bolstered by record investments, advanced clinical trials, and a government-backed focus on innovation.
And yet, for many U.S. institutions, Korean biotech remains a promising but distant signal—strong on potential, but lacking structure for meaningful engagement.
“We met excellent Korean companies,” one East Coast hospital innovation director told me. “But we don’t know what to do after the pitch.”
As a Korean American publisher who has spent 25 years bridging cultures and industries, I saw a rare opportunity: not just to showcase, but to curate. Not just to attend, but to activate.
That’s why we created K-BioSync 2025—a new kind of cross-border biotech engagement platform, designed not for scale, but for selectivity. Not for visibility, but for viability.
II. THE PROBLEM: Why Biotech Globalization Fails to Deliver
Too often, globalization in biotech is performative. Companies travel thousands of miles, attend expos, shake hands, collect
brochures—and return home with no action plan.
For Korean companies, the hurdles are systemic:
Regulatory uncertainty (especially around FDA readiness)
Communication gaps (cultural, legal, clinical)
Lack of U.S. partner trust due to unknown vetting
No post-event engagement structure
For U.S. institutions, the challenges are equally real:
No curated access to vetted Korean firms
Language, liability, and integration concerns
Limited knowledge of Korean IP, clinical ethics, and approval pathways
“Expo fatigue” — hundreds of booths, little alignment
“We don’t need more booths,” a New Jersey-based venture partner said. “We need less noise and more fit.”
It became clear: we don’t need another expo—we need a new framework.
III. THE SOLUTION: What K-BioSync Does Differently
K-BioSync 2025 is a pilot program launching in October 2025 in New Jersey. But it is not just an event. It is a model, co-hosted by two of the most credible institutions in the region:
Choose New Jersey, the state’s official economic development agency BioNJ, the leading voice of New Jersey’s life science ecosystem
Together, we’re building a program where every company is:
Selected through a structured application and screening process
Evaluated by a committee of U.S. legal, clinical, and capital experts
Matched to specific stakeholders, based on real alignment—not chance
Followed-up with structured support, reporting, and next steps
It’s not just a one-time summit. It’s a gateway with a roadmap.
IV. THE CONTEXT: Why New Jersey? Why Now?
New Jersey is uniquely positioned to become the U.S. beachhead for Korean biotech expansion:
Feature Why It Matters
13 of top 20 global pharma HQs present Access to industry giants
Choose NJ soft landing programs Legal, real estate, and visa support
Proximity to NYC Capital, media, and Korean diaspora network
Public-private infrastructure Coordinated support across agencies
K-BioSync is built inside this system, not beside it.
V. THE FORMAT: Structure with Intention
Selection:
Korean firms apply through a transparent portal. Applications are reviewed for:
Technical merit
Regulatory roadmap
U.S. market readiness Team capacity
Evaluation:
A U.S.-based committee, organized by BioNJ and partners, scores companies based on a matrix of: Product-market fit Licensing/partnering potential
Clinical alignment Legal/IP maturity
Cultural readiness
Matching:
Each selected company is given a customized schedule of: 1:1 stakeholder meetings (clinical, legal, VC, commercialization)
FDA orientation sessions IP/legal clinic briefings
Optional media briefing
Post-Engagement:
Unlike expos, every matched stakeholder is given a follow-up brief, with a 60-day re-engagement option. The Korean company receives support from BioNJ/Choose NJ liaisons to track progress.
VI. THE OUTCOMES: Use Cases from the Pilot Cohort
Example 1: NeuroCore Bio (Seoul)
Focus: CNS gene therapy
Challenge: No U.S. clinical contacts, limited IP clarity
Matched with: Hackensack Meridian Innovation
NY-based IP law firm
Korean-American biotech accelerator
Outcome: Term sheet discussion + soft landing inquiry
Example 2: LuminDx AI (Daejeon)
Focus: Machine learning diagnostics (oncology)
Matched with: Choose NJ data analytics sandbox
Investor group led by NJTech Angels
Outcome: Due diligence call scheduled + FDA strategy session
VII. MEDIA & STAKEHOLDER VISIBILITY
We are committed to turning this platform into a global signal of Korea–U.S. innovation alignment. We are engaging: Korean press (Maeil Bio, Chosun Biz, KORISE)
U.S. trade media (Stat News, Endpoints, BioSpace)
Public sector briefings for U.S. and Korean government ministries
Why does this matter? Because perception drives partnership. A curated platform deserves curated storytelling.
VIII. THE LONG GAME: K-BioSync 2026 and Beyond
K-BioSync is not a one-time experiment. It’s the first step in a repeatable model that can scale:
2025: Pilot cohort in NJ
2026: Full program with Korean government partners + larger cohort
I’ve published 295 issues over 25 years, but this is the first time I’ve built a platform from the ground up.
K-BioSync is not about quantity. It’s about credibility. It’s about being small enough to be real, and structured enough to grow.
To every Korean biotech founder reading this:
You don’t need to win a booth. You need to win trust. We’re here to help.
To every U.S. institution reading this:
This is not a showcase. It’s a system—designed for you, with you.
Let’s build the next chapter of biotech collaboration together.
What They Really Need AStrategicAddendum to K‑BioSync’s Role in Bridging Biotech Gaps
In the fast evolving world of cross border biotech, introductions are no longer enough.The real challenge lies not in visibility, but in readiness and fit.Throughout BIO International 2025, conversations on the expo floor revealed a crucial insight: Korean innovation is real—but mutual needs remain unmet.
What U.S. Institutions Are Actually Looking For
At the heart of every conversation with U.S. hospitals, CROs, and investors, a few themes kept surfacing. American partners are open—often eager—to collaborate with Korean biotech companies. Yet, they also expressed clear, unmet needs that go beyond what a typical expo booth can address.
First and foremost is regulatory preparedness. Many U.S.-based stakeholders asked pointed questions: “Does this company understand the FDA timeline? Have they mapped their Phase 1 readiness? What’s the reimbursement outlook?” In many cases, Korean firms fell short—not for lack of technology, but for lack
of localized strategy.
There was also a strong desire for companies with a clear U.S. clinical pathway—not just a compelling pipeline. Institutions need to see how that innovation will actually move through their system.
Another pain point was communication readiness. Investors and hospitals alike cited poorly translated investor decks, unclear clinical data summaries, and the absence of bilingual staff as real barriers to serious engagement.
Trust and due diligence also surfaced as key factors. Many U.S. stakeholders worry about follow-through and vetting. They want assurance that the company they meet will be responsive, transparent, and prepared to move forward. Customization, too, matters deeply. “We’re seeing the same generic pitch again and again,” said one VC. “It doesn’t speak to our focus areas.”
And lastly, the importance of post-event structure cannot be overstated. “We meet great people,” said one hospital innovation lead, “but then what? There’s no system to follow up.” The message is clear: connection without conversion is a wasted opportunity.
K-BioSync directly addresses these gaps. By offering FDA-readiness workshops, tailored U.S. clinical strategy sessions, professional bilingual IR material development, and a post-event CRM-based concierge system, it creates a true ecosystem of trust and delivery.
What Korean Biotech Companies Desperately Need
From the Korean side, the frustrations are just as real—and just as valid. Many companies attend expos year after year, spending tens of thousands of dollars, only to leave with little more than a handful of business cards and no clear path forward.
The number one concern? Access to actual decision-makers. “We meet marketing reps,” said one Korean startup founder. “We never meet the person who can say yes.”
There is also a glaring lack of understanding around the U.S. system. Reimbursement, patient recruitment, clinical trial regulations—all of it feels foreign. And without this knowledge, even the best tech can fall flat. Korean companies want guidance: not just encouragement, but true insight.
A third concern is brand credibility in the U.S. ecosystem. Even with good science, many Korean firms struggle to get noticed.
They ask, “How do we get taken seriously in the U.S.?” The answer lies in association. Co-branding with respected U.S. institutions like BioNJ and Choose New Jersey is not just symbolic—it’s strategic.
But the gaps aren’t just external. Many Korean companies also lack high-quality IR materials in English—whether it’s investor decks, product explainers, or video summaries. And most importantly, they lack structure. “We spend $50,000 to come here,” said another founder, “but there’s no framework. We don’t know who we’ll meet or how to follow up.”
K-BioSync gives Korean companies exactly that structure. By pre-matching participants, offering stakeholder profiles in advance, and supporting them with communication tools, K-BioSync helps convert presence into partnership. It’s a curated entry point—not an open-ended expo.
What This All Means
The global biotech partnership gap is not about interest. It’s about infrastructure.
Both sides—U.S. institutions and Korean biotech firms—want to work together. But they speak different operational languages. They plan on different timelines. They measure success with different metrics.
K-BioSync is not just a stage for meetings. It is a system for conversions.
It pre-qualifies participants, bridges knowledge gaps, and supports sustained engagement. That is what will make cross-border collaboration real—and replicable.
For the future of K-Bio, this is what they really need.
Participating Companies (KR)
Representative Pilot Cohort – Ready for Global Matching
1. Gencellmed (Oncolytic Virus / Immunotherapy)
Headquarters: Seoul, South Korea
Founded: 2019 (Spin-off from KIRAMS)
Technology: SMART platform combining tumor-targeting oncolytic viruses with immune modulators
Stage: Preclinical with 7 pipeline candidates
U.S. Readiness:
Oncology remains a high-demand field in the U.S. Well-positioned for proof-of-concept trials in collaboration with U.S. hospitals Needs:
4. Cyrus Therapeutics (Targeted Protein Degradation - TPD / Oncology)
Headquarters: Seoul, South Korea
Founded: 2019
Technology: TPD platform with 7 candidates for hematologic and solid tumors
Stage: Preclinical
U.S. Readiness:
TPD is a hot sector in the U.S. biotech investment landscape Needs:
IND planning
U.S. VC engagement
Clinical site partnerships
5. Parataxis (Drug Development / U.S. SPAC Strategy)
Headquarters: South Korea
Founded: N/A
Technology: Multi-pipeline biotech startup preparing for U.S. SPAC listing
Stage: U.S. market entry / financing stage
U.S. Readiness:
Seeking acceleration into U.S. via reverse merger or SPAC Needs:
Legal & investor advisory connections
U.S. IR material support
Corporate communications and positioning
6. SK Biopharmaceuticals (CNS / Commercial Products)
Headquarters: Pangyo, South Korea
Founded: 2011 (Spin-off from SK Holdings)
Technology: CNS-focused therapeutics, including Xcopri, FDA-approved for epilepsy
Stage: Commercial (active in U.S. market)
U.S. Readiness:
U.S. manufacturing (Puerto Rico), and sales network established Needs:
Clinical partnerships for expanded indications
Media coverage & branding support
Reimbursement & patient access optimization
Target Partners (US)
Realistic & High-Potential U.S. Partners for K-BioSync 2025
As Korea’s biotech industry continues to scale its innovation globally, the success of cross-border collaboration hinges on strategic U.S. partnerships that are both realistic and catalytic. For Korean startups looking to establish clinical validation, investment access, or strategic alignment in the United States, the following U.S.-based institutions represent high-potential partners—selected not by size alone, but by their alignment with the mission of K-BioSync 2025: enabling curated, cross-border biotech success.
Hospitals & Clinical Institutions
Mass General Brigham Innovation (Boston, MA)
Mass General Brigham stands at the forefront of clinical research and digital health innovation. As one of the most prestigious hospital networks in the United States, it actively engages in early-stage proof-of-concept (PoC) trials in oncology, rare disease, and diagnostics.
Fit with K-BioSync: Korean startups offering PoC-ready technology in gene therapy, early cancer detection, or immune diagnostics may find ideal trial partners here.
Needs & Priorities: Hospital-driven trials with a clear clinical focus, regulatory preparedness (FDA-aligned), and strong translational potential.
Hackensack Meridian Health Innovation (New Jersey)
The largest integrated healthcare network in New Jersey, Hackensack Meridian’s innovation arm supports real-world testing and collaboration across its clinical ecosystem.
Fit with K-BioSync: Localized clinical validation and AI-powered healthcare applications are a natural match, especially for firms entering the U.S. Northeast.
Needs & Priorities: Demonstrable data integration, regional partnerships, and scalable AI diagnostics or patient monitoring systems.
Venture Capital & Investment Firms
Vie Ventures (Boston, MA)
Vie Ventures targets immunology, autoimmune, and rare disease innovations, managing a $75M fund with a deep interest in biologics and cell therapies.
Fit with K-BioSync: Series B-stage Korean companies with robust IP and Phase 1 readiness in immunotherapy may attract serious interest.
Needs & Priorities: A clear FDA engagement roadmap, preclinical or early clinical data, and a well-defined U.S. market entry plan.
Third Rock Ventures (Boston, MA)
This life science-focused VC has incubated some of the biggest biotech successes including Bluebird Bio and Editas Medicine, with a total AUM of $3.8B.
Fit with K-BioSync: Advanced platform companies from Korea entering first-in-human or early-phase clinical trials.
Needs & Priorities: Disruptive science, strong intellectual property, and FDA pathway clarity.
Vivo Capital (Palo Alto / Global)
Operating a $5.3B portfolio, Vivo bridges Asia and North America, investing across therapeutics, diagnostics, and digital health.
Fit with K-BioSync: Korean firms looking for pan-Asia/U.S. growth capital and cross-border strategic partnerships.
Needs & Priorities: Late preclinical to commercial-stage opportunities, with global scalability and strong data.
Accelerators & Institutional Partners
SOSV / IndieBio (Newark, NJ & NYC)
A globally renowned biotech accelerator with seed investment and full-time lab support, SOSV’s IndieBio East branch is a strong resource for Korean biotech startups.
Fit with K-BioSync: Korean innovators needing U.S. entry scaffolding, mentorship, and early visibility.
Needs & Priorities: Founders with bold ideas, pre-seed or seed-stage firms ready to engage in structured U.S. programs.
Flagship
Pioneering (Cambridge, MA)
The incubator behind Moderna, Flagship has a track record of identifying and scaling groundbreaking life science startups. Fit with K-BioSync: University spin-outs and early research-based Korean biotech firms seeking cradle-to-IPO trajectories.
Needs & Priorities: High scientific originality, platform potential, and visionary founders.
Foresite
Capital (SF / LA / NY)
Known for later-stage health investments, Foresite manages over $900M and focuses on companies close to commercialization.
Fit with K-BioSync: Korean firms looking to scale in the U.S. with clinical data and market strategy already established. Needs & Priorities: Revenue visibility, regulatory roadmap execution, and measurable patient outcomes.
K-BioSync 2025 is designed to align these U.S. stakeholders with Korea’s most promising biotech innovators. By understanding their unique needs—whether it’s FDA-pathway clarity, U.S. trial partners, or scale-ready IP—we increase the success rate of meaningful global partnerships.
Media Plan & Coverage Strategy Amplifying Cross‑Border Visibility for Korean & U.S. Biotech Stakeholders
Media as Infrastructure: Building Visibility, Building Trust. In today’s global biotech ecosystem, visibility isn’t an afterthought—it is a fundamental layer of infrastructure. Especially for cross-border collaboration, media presence becomes the foundation upon which credibility, partnerships, and capital flow are built.
K-BioSync 2025 recognizes this reality and integrates a comprehensive bilingual media strategy into the core of its pilot program. This is not just a showcase—it’s a content-powered gateway. Designed to support Korean biotech companies seeking meaningful U.S. partnerships, and U.S. institutions aiming to tap into Korea’s innovation economy, K-BioSync places equal weight on what happens on the ground and what is amplified beyond it.
The goal is clear: to position Korean biotech startups as serious players in the U.S. market, and to introduce U.S. hospitals, CROs, and investors to Korea’s emerging biomedical excellence—not just through meetings, but through storytelling. Through carefully curated press features, video interviews, and bilingual case studies, the event’s outcomes will echo far beyond the meeting room.
Media coverage will be channeled through both U.S. and Korean outlets. On the U.S. side, we are targeting respected names like Endpoints News, STAT, BioPharma Dive, and TechCrunch Bio, as well as regional innovation outlets such as NJ Biz and ROI-NJ. In Korea, our outreach includes 조선비즈, 헬로디디, 바이오스펙테이터, 한경 BIO Insight, and other specialized publications that shape public and institutional perception.
To support this, KORISE will produce a set of premium editorial assets, including a bilingual press kit, a 4-page media summary, a 6-page special feature published in both digital and print, and post-event video interviews. These deliverables will live not only in press distribution channels, but in a centralized media archive hosted on korise.co—accessible for future reference, investor pitching, and institutional engagement.
This multi-layered media plan is also a long-term play. By positioning K-BioSync as a trusted and data-rich entry point into the U.S. biotech landscape, we aim to build an enduring media footprint that supports the event’s scale-up in 2026 and beyond. The platform is designed to grow—from pilot to portal, from local to global.
Ultimately, media is not just about visibility. It’s about building trust across borders. And trust is what drives deals.
K-BioSync 2025 isn’t simply reporting on innovation. It is writing its next chapter.
A Strategic Gateway to U.S.–Korea Bio Collaboration
How to Join K-BioSync 2024
Who Should Apply
Korean biotech, diagnostics, or medtech companies seeking U.S. entry
Firms preparing for FDA strategy, clinical trials, or strategic funding
Companies with strong IP and scalable innovation looking to validate in the U.S. market
Participation Process, Submit Application Materials Company overview, pitch deck, desired collaboration type Undergo Evaluation by U.S. Advisory Committee
Led by experts from BioNJ, Choose NJ, and partner institutions
Get Matched with Relevant U.S. Partners Hospitals, VCs, CROs, research hubs (Pre-arranged 1:1 meetings)
Benefits for Selected Companies
Meet qualified U.S. partners seeking global collaboration Showcase your tech with institutional support and visibility Media exposure through U.S. and Korea press coverage
Be part of a curated pilot to be scaled in 2026 Apply Now
Email: sylvia@mpluscreative.com
U.S. Office: +1-201-224-7500
Press & Media: info@mpluscreative.com
For U.S. Hospitals, Investors & Institutions Curated Access to Korea’s Most Promising Bio Ventures
Who Should Join
U.S.-based hospitals, academic medical centers, CROs
VCs/PE firms looking for APAC pipeline and co-investment partners
Innovation hubs, accelerators, and biotech cluster leaders
How to Join
Register Your Interest via Partner Inquiry Form
Receive Curated Company Profiles
Evaluated and pre-qualified Korean biotech ventures
Join October 15–17 Onsite or Virtually 1:1 meetings, deal-making sessions, private briefings
Why Participate
Gain early access to high-growth biotech ventures from Korea Engage in strategic discussions on regulatory pathways, clinical readiness
Gain exposure in Korean and U.S. bio/tech industry media Expand your Asia collaboration portfolio through a government-backed gateway
Deadline: August 31, 2025
K-BioSync 2025
Where Innovation Meets Intention. Global Collaboration Begins With Curated Trust.
“Korea changed the sound of the world. Now, we’re changing its science.” The next chapter of Korean global influence will not be on stage but in the lab, in the clinic, and in the boardroom.
K-BioSync 2025 is not just an event.
It is a precision gateway—designed to transform promising Korean biotech into investable, partner-ready innovation in the U.S.
By curating trust-based connections with hospitals, VCs, CROs, and regulators, we unlock what expos alone cannot: strategic access, storytelling power, and follow-through.
A blueprint for Korea-U.S. biotech collaboration
A living archive of curated companies, partners, and needs
A starting point for a multi-year, multi-market growth platform
Looking Ahead: What Comes Next
Spring 2026: Global K-Bio Gateway (U.S. Expansion Program) Fall 2025: K-BioSync Reports + Investment Briefings
2025–2026: Institutional collaborations, media amplification, and follow-up roundtables
